The tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is a powerful lung carcinogen in animal models and is considered a causative factor for lung cancer in people who use tobacco products. NNK undergoes metabolic activation-a critical step in its mechanism of carcinogenesis-to an intermediate which reacts with DNA to form pyridyloxobutyl DNA base and phosphate adducts. Another important metabolic pathway of NNK is its conversion to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), which similarly forms pyridylhydroxybutyl DNA base adducts that have been characterized previously. In this study, we investigated the potential formation of pyridylhydroxybutyl DNA phosphate adducts. We report the characterization and quantitation of 107 structurally unique pyridylhydroxybutyl DNA phosphate adducts in the lungs of rats treated chronically with a carcinogenic dose of 5 ppm of NNK in their drinking water for up to 70 weeks, by using a novel liquid chromatography-nanoelectrospray ionization-high-resolution tandem mass spectrometry method. Our findings demonstrate that pyridylhydroxybutyl phosphate adducts account for 38-55 and 34-40% of all the measured pyridine-containing DNA adducts in rat lung and liver, respectively, upon treatment with NNK. Some of the pyridylhydroxybutyl DNA phosphate adducts persisted in both tissues for over 70 weeks, suggesting that they could be potential biomarkers of chronic exposure to NNK and NNAL. This study provides comprehensive characterization and relative quantitation of a panel of NNK/NNAL-derived DNA phosphate adducts, thus identifying NNK as the source of the most structurally diverse set of DNA adducts identified to date from any carcinogen.
Introduction
All tobacco products contain 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific nitrosamine which is a powerful pulmonary carcinogen in rats, mice and hamsters, inducing mainly adenocarcinoma, independent of its route of administration (1) (2) (3) (4) . For example, in one recent study, F-344 rats were treated with NNK in the drinking water (5 ppm) for up to 90 weeks (5) . All treated rats had histologically confirmed lung tumors, most of which were classified as carcinoma; metastases to the pancreas were also observed.
In rodents and humans, NNK is extensively metabolized to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) which is also a potent and selective pulmonary carcinogen with activity similar to that of NNK (4, 5) . All humans who use tobacco products-either cigarettes or smokeless tobacco-have NNAL in their urine (6) (7) (8) (9) (10) (11) . NNK is considered as one likely cause of lung cancer-particularly adenocarcinoma of the lung-in cigarette smokers (3, 12) . Consistent with its organospecificity for the lung, a recent epidemiologic study has also demonstrated Carcinogenesis, 2018, Vol. 39, No. 2, 232-241 doi:10.1093/carcin/bgx135 Advance Access publication November 29, 2017 Original Article a significantly elevated risk of lung cancer in non-smokers who were exclusive users of oral smokeless tobacco products (chewing tobacco and snuff), which have a less complex mixture of carcinogens than cigarette smoke, and in which NNK is one of the most abundant strong carcinogens (13) . NNK and the related carcinogen N'-nitrosonornicotine are considered 'carcinogenic to humans' by the International Agency for Research on Cancer (1) .
A critical step in carcinogenesis by nitrosamines such as NNK and NNAL is formation of DNA adducts, which can cause miscoding and permanent mutations in growth control genes such as K-RAS (14, 15) . Identification of the relevant DNA adducts can significantly enhance our understanding of mechanisms of cancer induction, potentially leading to biomarkers for the identification of particularly susceptible users of tobacco products and providing insights for cancer prevention.
Metabolic activation of NNK to intermediates that react with DNA to form adducts occurs by α-hydroxylation, a cytochrome P450-catalyzed pathway that is typical for nitrosamines (4, 16) . α-Hydroxylation of both the methylene and methyl carbons is observed; only the latter is considered here. As shown in Figure 1 , α-hydroxylation of the NNK methyl group produces the unstable intermediate α-hydroxymethylNNK (4) which spontaneously loses formaldehyde to produce diazohydroxide 6. This intermediate can further decompose to diazonium ion 8, which is highly electrophilic and reacts with DNA to produce pyridyloxobutyl (POB)-base adducts such as 7-[4-(3-pyridyl)-4-oxobutyl]Gua (7-POB-Gua), O 6 -POB-dGuo and O 2 -POB-dThd, as well as phosphate adducts such as B 1 p(POB)B 2 , which have been previously characterized (and were referred to as B 1 popB 2 ) (5, (17) (18) (19) (20) (21) . The NNK metabolite NNAL (2) also undergoes α-hydroxylation to similarly produce diazonium ion 9 (4, 22) . Diazonium ion 9 reacts with DNA bases to form 4-[(3-pyridyl)-4-hydroxybutyl] (PHB)-base adducts which have been previously characterized (23, 24) , but also has the potential to form phosphate adducts in DNA such as B 1 p(PHB) s B 2 , where PHB represents pyridylhydroxybutyl and the subscript s represents 'straight chain' (Figure 1 ). Diazonium ion 9 further rearranges to carbocation 10 (22), which can also form adducts with both DNA bases and phosphate [e,g., B 1 p(PHB) b B 2 , where the subscript b represents 'branched']. Thus, DNA phosphate adducts of NNAL arising through intermediates 9 and 10, and collectively called B 1 p(PHB)B 2 , have not been previously investigated and are the subject of this report.
We developed a novel liquid chromatography (LC)-nanoelectrospray ionization (NSI)-high-resolution tandem mass spectrometry (HRMS/MS) method for analysis of the potentially complex array of DNA phosphate adducts formed in the NNAL pathway of NNK metabolism. DNA phosphate adducts from this pathway were characterized in reactions of NNALOAc (3), a stable precursor to intermediate 5 formed in NNAL metabolism, with DNA, and in lung and liver DNA of rats treated with 5 ppm of NNK in the drinking water for 10, 30, 50 and 70 weeks, conditions which cause lung tumors in all animals as noted above. 
Materials and methods

Materials and chemicals
Synthesis of chemical standards
In vitro and in vivo DNA samples
In the in vitro study, CT-DNA (2 mg) was incubated with NNALOAc (10 mg) in the presence of porcine liver esterase (4 units) in 0.1 M phosphate buffer (1 ml, pH 7.0) at 37°C for 12 h. NNALOAc is a chemically activated form of NNAL, which in the presence of esterase forms the same reactive intermediate 5 as produced in metabolism of NNAL by P450s (Figure 1) The in vivo DNA samples were from lung and liver tissues of male F-344 rats (n = 5 at each time points) treated chronically with 5 ppm of NNK in drinking water for 10, 30, 50 and 70 weeks, as described previously (5) . DNA was isolated using our previously developed protocol (20) , and stored at −20°C until analysis. 
DNA hydrolysis and sample preparation
The DNA samples were dissolved in 0. (20) . The remaining hydrolysate was filtered through 10 K centrifugal filters (Ultracel YM-10, Millipore), and the filtrates were loaded on 30-mg Strata X cartridges (Phenomenex) activated with 2 ml of MeOH and 2 ml of H 2 O. The cartridges were washed with 2 ml of H 2 O and 1 ml of 10% MeOH sequentially and finally eluted with 2 ml of 50% MeOH. The 50% MeOH fraction containing analytes was concentrated to dryness in a centrifugal evaporator. The residue was re-dissolved in 10 μl of deionized H 2 O prior to analysis by LC-NSI-HRMS/MS.
LC-NSI-HRMS/MS analysis
The analysis was performed on an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific, Waltham, MA) with full scan, selected-ion monitoring (SIM) and product ion scan analysis using Orbitrap detection with internal calibration using the EASY-IC feature of the Fusion instrument. A nanoLC column (75 μm i.d., 360 μm o.d., 17 cm length and 15 μm orifice) packed with Luna C 18 bonded separation media (Phenomenex, Torrance, CA) was used. The mobile phase consisted of 5 mM NH 4 OAc and CH 3 CN. A 5 μl injection loop was used, and the sample (4 μl) was loaded onto the capillary column with a 900 nl/min flow rate under the initial conditions for 6.5 min at which point the injection valve position was switched to take the injection loop out of the flow path and the flow rate was reduced to 300 nl/min. Separation on the column was performed using a linear gradient with increasing CH 3 CN from 2 to 18% over 24 min, followed by ramping to 90% CH 3 CN within 2 min and holding at this composition for an additional 3 min. The gradient was then returned to 2% CH 3 CN in 1 min, and the system was re-equilibrated at this mobile phase composition for 6 min at 900 nl/min before the next injection. The spray voltage of the mass spectrometer was 2.2 kV. The capillary temperature was 300°C, and the S-Lens RF Level was 60%. A multiplexed SIM analysis was performed whereby each ion mass of interest is sequentially isolated by the quadrupole and stored in the ion routing multipole, and upon collection of all masses of interest, all ions are transported into the Orbitrap for analysis. The [M + H] + ions of all possible phosphate adducts listed in Table 1 were analyzed in this fashion using an isolation window of 3 m/z, Automatic Gain Control (AGC) target of 50 000, maximum inject time of 100 ms and a resolution of 60 000. The product ion scan was performed using higherenergy collisional dissociation (HCD) fragmentation with a normalized collision energy of 25 units, isolation widths of 1 Da for all the precursor ions and product ion analysis performed with a mass range of m/z 100-800 at a resolution of 15 000. The accurate mass tolerance used for extraction of precursor and fragment ion signals was 5 ppm.
The quantitative analysis of Cp(PHB) s C and Tp(PHB) s T was performed using accurate mass extracted ion chromatograms of the product ion scan data of m/z 328. Figure 7 , available at Carcinogenesis Online), and their contribution to signal intensity was added when estimating the levels of these adducts. The average signal response of the Cp(PHB) s C and Tp(PHB) s T calibration curves was used to estimate the levels of other phosphate adducts.
All data are presented as mean ± standard deviation (SD). Comparison of adduct levels at different time points were performed using analysis of variance (ANOVA) with Bonferroni correction for multiple comparisons. A P value less than 0.05 was considered significant. Table 1 summarizes the possible numbers of DNA phosphate adduct isomers which could be formed from intermediates produced in the metabolism of NNAL. There can be 10 different combinations of the four nucleobases, and there can be different stereoisomers for each combination due to the chiral centers in the structure. Thus, because of the tetrahedral structure of the phosphate group and the chiral carbinol carbon, there can be four possible isomers of B 1 p(PHB) s B 2 with the same nucleobase combination, and eight isomers with different nucleobase combinations, resulting in a total of 64 different possible B 1 p(PHB) s B 2 adducts. For B 1 p(PHB) b B 2 adducts, an additional chiral center is introduced on the methyl-bearing carbon, so the adducts with the same nucleobase combination can potentially form eight isomers, while adducts with a different nucleobase combination Table 1) . The presence of Cp(PHB) s C and Tp(PHB) s T in rat tissue DNA was confirmed by comparison of their LC-MS retention times and product ion scan spectra to those of the synthesized standards. Figure 2A shows the chromatogram for standard Cp(PHB) s C and Figure 2B the corresponding chromatogram of a DNA sample from rat lung upon treatment with NNK in the drinking water for 30 weeks. The first two peaks in Figure 2B The structures of the other eight nucleobase combinations were characterized based on the accurate masses of the precursor ions and the corresponding fragment ions. With Ap(PHB) C as an example, the exact mass of its precursor ion of m/z 690.2396 was extracted from the SIM scan data upon analysis of lung DNA from a 10 week-treated rat, and 12 peaks were detected ( Figure 2E ), indicating the presence of at least 12 isomers. The peak shapes and retention times of the major fragment ion, m/z 328.0945, and the other major fragment ions of each of the 12 peaks matched the SIM data from the parent ion ( Figure 2E Table 1 , available at Carcinogenesis Online). At least six isomers were observed for each combination of B 1 p(PHB)B 2 adducts. The three most abundant adduct types formed were Cp(PHB)T, Ap(PHB)T and Ap(PHB)C, which accounted for 24, 21 and 18% of the total B 1 p(PHB)B 2 adducts, respectively (Supplementary Figure 10 , available at Carcinogenesis Online).
Results
Characterization and quantitation of pyridylhydroxybutyl phosphate adducts
Using HCD fragmentation, the product ion spectra of both Cp(PHB) s C and Tp(PHB) s T generated several major fragment ions (Supplementary Figure 11, Figure 3A) . A decrease in adduct levels over the course of the study was observed for all the combinations. For example, the level of Ap(PHB)C decreased from 441 ± 38 fmol/mg DNA at 10 weeks of treatment to 210 ± 77 fmol/mg DNA at 70 weeks of treatment (P < 0.05). In the lung, the three most abundant adducts were Cp(PHB)T, Ap(PHB) C and Gp(PHB)T, which accounted for 20-30, 16-19 and 10-17% of the total B 1 p(PHB)B 2 phosphate adducts, respectively ( Figure 3B) . However, the formation patterns were different between the two tissues. While the adduct levels of most combinations were maximal at 10 weeks in the liver, the levels of most combinations were the highest at 30 weeks in the lung. For example, the level of Ap(PHB)C in the lung at 30 weeks was 1410 ± 76 fmol/mg DNA, significantly higher than the levels at 10, 50 or 70 weeks (P < 0.05).
Different levels of isomers of the same combination of B 1 p(PHB)B 2 were observed for all 10 combinations in both liver and lung ( Figure 3C -E and Supplementary Figures 12 and 13 , available at Carcinogenesis Online). For example, the level of Gp(PHB) T-1 was significantly higher than the other isomers of Gp(PHB)T in the liver throughout the study ( Figure 3C ). The formation patterns of each isomer from some combinations were similar. For example, the levels of both Cp(PHB) s C-1 and Cp(PHB) s C-2 in the liver were maximal at 10 weeks and decreased afterwards ( Figure  3D ). However, the formation patterns of isomers from some other combinations were different. For example, the level of Tp(PHB) s T-1 in the liver was maximal at 10 weeks and decreased afterwards (P < 0.05, Figure 3E ), while the levels of Tp(PHB) b T-1 and Tp(PHB) b T-2 reached a peak at 30 and 50 weeks, respectively. The level of Tp(PHB) b T-3 was not significantly changed over the course of the study (P = 0.14, Figure 3E ).
Comparison of DNA phosphate and base adducts formed by NNK
To determine the relative proportion of B 1 p(PHB)B 2 adducts to the total known pyridine-containing DNA adducts formed by NNK, the levels of the other three types of DNA adducts [PHB base adducts, POB base adducts and B 1 p(POB)B 2 adducts], were measured or obtained from our previous studies of rats from the same treatment groups (Table 2) -PHB-dThd) and 7-[4-(3-pyridyl)-4-hydroxybut-1-yl]guanine (7-PHB-Gua)-were measured in rat liver DNA in this study using our previously developed method (24) . The total amount of the two major PHB base adducts ranged from 466 to 1050 fmol/ mg DNA in liver DNA over the course of the study. The levels of POB base adducts and B 1 p(POB)B 2 phosphate adducts in the liver and lung were reported previously (5, 21) . In rat liver, the most abundant type of DNA adducts were POB base adducts, which accounted for 40-44% of the total measured DNA adducts, followed by B 1 p(PHB)B 2 phosphate adducts (34-40%), PHB base adducts (14-21%) and B 1 p(POB)B 2 adducts (2-4%) ( Figure 4A ; Table 2 ); while in the lung, the most abundant DNA adducts were B 1 p(PHB)B 2 phosphate adducts, which accounted for 38-55% of the total measured DNA adducts, followed by POB base adducts (32-48%), PHB base adducts (10-13%) and B 1 p(POB)B 2 phosphate adducts (1-2%) ( Figure 4B and Table 2 ). Methyl-DNA base adducts are also formed by NNK due to α-hydroxylation on its methylene carbon (4, 5) , and the formation and characterization of methyl-DNA phosphate adducts in NNK-treated rats will be reported separately.
In -PHB-dGuo) was also detected and quantified in NNALOAc-treated CT-DNA. The relative levels of total B 1 p(PHB)B 2 adducts and total PHB base adducts were comparable to those in the DNA samples from 
Discussion
The results of this study were unexpected with respect to both the extent and diversity of DNA phosphate adducts-B 1 p(PHB)B 2 -formed in the NNAL pathway of NNK metabolism. Thus, our previous study of B 1 p(POB)B 2 adducts formed in NNK metabolism demonstrated that they comprised a relatively small percentage of total adduct formation ( Figure 4) . In contrast, the present results show that B 1 p(PHB)B 2 adducts represent a sizable slice of the NNK-DNA adduct pie in rat liver and lung (Figure 4) . Notably, our LC-NSI-HRMS/MS method revealed a surprising variety of NNAL-derived DNA phosphate adducts, explainable by the recognition that rearrangement of diazonium ion 9 to carbocation 10 is a substantial in vivo pathway of NNAL-DNA adduct formation. Thus, we demonstrate an unprecedented diversity of structurally unique DNA adducts formed from a single Values are presented as means ± SD (n = 3 or 5).
a
The data of total B 1 p(POB)B 2 phosphate adduct levels in both tissues, and POB base adduct levels in rat liver are from Ma et al. (21) . carcinogen-NNK. Taken together with our previous study in which we characterized 30 B 1 p(POB)B 2 adducts, we have now identified 137 novel and structurally distinct DNA-phosphate adducts in tissues of rats treated with NNK, far greater than reported to date from any other carcinogen. Most DNA adduct studies have focused on the interaction of chemicals with DNA nucleobases rather than the inter-nucleotide phosphate groups. Studies of DNA phosphate adducts have demonstrated however that they have longer half-lives than their corresponding base adducts in animals treated with alkylating agents (25) (26) (27) (28) . For example, after administration of a single dose of ethylnitrosourea to mice, the half-lives of ethyl phosphate adducts in the major tissues were 10−15 weeks, compared to the half-lives of 30−220 h of the corresponding O 6 -ethylguanine base adduct (28) . While the levels of most DNA base adducts decreased over time upon chronic treatment of rats with NNK (5), our previous study demonstrated that the levels of some NNK-derived B 1 p(POB)B 2 adducts were persistently high in the same rats over the 70 weeks of treatment (21) . Consistent with those observations, some of the B 1 p(PHB)B 2 phosphate adducts in the current study demonstrated persistence in rats over the 70 weeks of treatment. These findings indicate that these DNA phosphate adducts could potentially be used as biomarkers for chronic exposure to tobacco-specific carcinogens in humans. Exploring this approach would most likely involve focusing on a particular isomer such as Tp(PHB) b T-3 in lung. The first step would be further characterization of the selected isomer. This could be accomplished by synthesis of the appropriate diastereoisomeric precursors related to 1-(3-pyridyl)-1,3-butanediol, then reaction of these with the selected dinucleotide phosphate followed by isolation and characterization. With specific standards in hand, analytical methods could be developed for quantitation in cellular DNA from human lung or oral tissue. Based on the high sensitivity and selectivity of LC-NSI-HRMS/ MS analysis, this research direction appears feasible.
As noted above, B 1 p(PHB)B 2 phosphate adducts are formed to a greater extent than B 1 p(POB)B 2 phosphate adducts in rats treated with NNK. In rat liver, the levels of B 1 p(PHB)B 2 phosphate adducts (878-2140 fmol/mg DNA) were significantly higher than B 1 p(POB)B 2 phosphate adducts (89-190 fmol/mg DNA). Similarly, in the lung, the levels of B 1 p(PHB)B 2 phosphate adducts were 3950-8160 fmol/mg DNA, compared to 218-475 fmol/mg DNA of B 1 p(POB)B 2 phosphate adducts. These differences were possibly due to the pharmacokinetic properties of NNK. When NNK is administered to rats, it is rapidly converted to NNAL. Although NNAL and NNK are in equilibrium, the equilibrium is strongly shifted toward NNAL in rats (4, 29) . Moreover, the half-life of NNAL in rats is 298 min, while that of NNK is only 25 min (30). Therefore, NNAL predominates over NNK in the rat circulation system (30, 31) . Since B 1 p(PHB)B 2 phosphate adducts were formed from NNAL, while B 1 p(POB)B 2 adducts were from NNK, this is one explanation for the higher levels of B 1 p(PHB)B 2 than B 1 p(POB)B 2 adducts. Indeed, the relative amount of total pyridine-containing DNA adducts from NNAL [B 1 p(PHB)B 2 plus PHB-base, 51-67%] was higher than that from NNK [B 1 p(POB)B 2 plus POB-base, 33-49%] in the lung. Similarly, slightly higher levels of NNALderived adducts (52-57%) than NNK-derived adducts (43-48%) were observed in the liver. Interestingly, POB base adducts were more abundant than B 1 p(POB)B 2 phosphate adducts, while PHB base adducts were less abundant than B 1 p(PHB)B 2 phosphate adducts. This suggests that NNK-derived base and phosphate adducts are either formed or repaired in a different manner than NNAL-derived base and phosphate adducts. However, the repair mechanism of the NNK/NNAL-derived DNA phosphate adducts is still unclear, and further studies are warranted.
The biological significance of the newly characterized NNK/ NNAL-derived B 1 p(PHB)B 2 phosphate adducts is unclear. Studies on other modifications of phosphate groups in DNA suggest some potential effects, including inhibiting DNA metabolic enzymes (25, 32, 33) , affecting DNA helicases (34) (35) (36) and interfering with the binding of DNA to other macromolecules (37) . Similar effects could be caused by the NNK-derived phosphate adducts, potentially leading to detrimental biological consequences; therefore, further studies of their effects on DNA repair processes and other biological effects are needed.
In summary, we applied our highly sensitive and selective LC-NSI-HRMS/MS methodology to characterize and quantify 54 and 107 previously unknown pyridylhydroxybutyl DNA phosphate adducts formed in liver and lung, respectively, of F-344 rats as the result of exposure to the tobacco-specific carcinogen NNK. These adducts are formed via NNK metabolism to NNAL and subsequent bioactivation of NNAL. Levels of some of these newly identified adducts in lung and liver of NNK-treated rats were persistent over the 70 weeks of treatment. These novel adducts could potentially serve as biomarkers of NNK exposure and carcinogenesis in humans.
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